Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 6, 1999, Pages 1379-1382

  Carmeli, Yehuda ^a,b   Troillet, Nicolas ^a   Eliopoulos, George M ^a   Samore, Matthew H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COMORBIDITY; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

EID: 0033059706     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.6.1379     Document Type: Article

References (14)

1. Basustaoglu, A. C., H. Gun, M. A. Saracli, M. Baysallar, and T. Haznedaroglu. 1995. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 14:469-470.
2. Carmeli, Y., N. Troillet, A. W. Karchmer, and M. H. Samore. Pseudomonas aeruginosa: health and economic impact of antibiotic resistance and emergence of resistance. Arch. Intern. Med., in press.
3. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. McKenzie. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383.
4. Cometta, A., J. D. Baumgartner, D. Lew, W. Zimmerli, D. Pittet, P. Chopart, U. Schaad, C. Herter, P. Eggimann, O. Huber, et al. 1994. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob. Agents Chemother. 38:1309-1313.
5. D'Agata, E. L., L. Vekataraman, P. DeGirolami, and M. Samore. 1997. Molecular epidemiology of ceftazidime-resistant gram-negative bacilli in a nonoutbreak setting. J. Clin. Microbiol. 35:2602-2605.
6. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., R. H. Johnson, S. O. Heard, R. G. Wunderink, J. W. Caldwell, J. J. Schentag, J. A. Siami, R. L. Zameck, D. C. Haverstock, H. H. Reinhart, and R. M. Echols. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastin. Antimicrob. Agents Chemother. 38:547-557.
7. Garner, J. S., W. R. Jarvis, T. G. Emori, T. C. Horan, and J. M. Hughes. 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16:128-140.
8. Harris, A., C. Toress-Vierra, L. Ventakataraman, P. C. DeGirolami, M. H. Samore, and Y. Carmeli. Epidemiology and clinical outcomes of infections with multi-resistant Pseudomonas aeruginosa. Clin. Infect. Dis., in press.
9. Jaccard, C., N. Troillet, S. Harbarth, G. Zanneti, D. Aymon, R. Schneider, R. Chiolero, B. Ricou, J. Romand, O. Huber, P. Ambrosseti, G. Praz, D. Lew, J. Bille, M. P. Glauser, and A. Commeta. 1998. Prospective randomized comparison of imipenem-cilastin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. Agents Chemother. 42:2966-2972.
10. Milatovic, D., and I. Braveny. 1987. Development of resistance during antibiotic therapy. Eur. J. Clin. Microbiol. 6:234-244.
11. Miro, E., F. Navarro, F. March, F. Sanchez, and B. Mirelis. 1995. Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem. Eur. J. Clin. Microbiol. Infect. Dis. 14:731-732.
12. Pechere, J. C., and I. R. Vladoianu. 1992. Development of resistance during ceftazidime and cefipime therapy in a murine peritonitis model. J. Antimicrob. Chemother. 29:563-573.
13. Quinn, J. P., E. J. Dudek, C. A. DiVincenzo, D. A. Lucks, and S. A. Lerner. 1986. Emergence of resistance to imipenem during therapy of Pseudomonas aeruginosa infections. J. Infect. Dis. 154:289-294.
14. Troillet, N., M. H. Samore, and Y. Carmeli. 1997. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility pattern. Clin. Infect. Dis. 25:1094-1098.